BRIGHT MINDS BIOSCIENCES INC

DRUG

Latest QuantConomy context for DRUG: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class

stock

Primary venue

NASDAQ

Recent signals

SEC filings

Asset profile

QuantConomy has a structured record for DRUG. More descriptive asset metadata will appear here when the platform record includes it.

Latest signal rows

Recent signals for DRUG

Scored rows are pulled from the same signal API used by the digests.

Signal	Direction	Score	Observed	Reason
volume sustained dry up	slightly bullish	76	Jul 6, 07:11 PM	DRUG sustained volume dry-up: 4% of expected volume for Monday 19:00 UTC, price up 1.09% (strength 76)
volume sustained dry up	neutral	54	Jul 6, 05:40 PM	DRUG sustained volume dry-up: 13% of expected volume for Monday 17:00 UTC, price flat 0.30% (strength 54)
volume sustained dry up	neutral	53	Jul 6, 04:36 PM	DRUG sustained volume dry-up: 13% of expected volume for Monday 16:00 UTC, price flat 0.44% (strength 53)

OWNERSHIP signals are experimental: historical 13D/G coverage is still being backfilled, so results may be sparse or empty.

Market	Exchange	Source	Asset record
DRUG	NASDAQ	alpaca	Bright Minds Biosciences Inc. Common Stock
DRUG	NASDAQ	alphavantage	Bright Minds Biosciences Inc
DRUG	NASDAQ	fmp	Bright Minds Biosciences Inc.

Buys, last 90d

Sells, last 90d

Rows

Date	Insider	Role	Type	Shares	Price	Value	Filing
Apr 28, 2026	Cormorant Asset Management, LP	Insider	sale	109,331	$89.50	$9,785,125	4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.